Treatment of the Acquired Immune Deficiency Syndrome

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 1986 May 1

PMID 2424929

Citations 2

Authors

S Gupta

M S Gottlieb

Affiliations

Soon will be listed here.

Abstract

The acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) are sequelae of immune system injury initiated by a novel human retrovirus [human T-lymphotrophic virus strain III/lymphadenopathy-associated virus (HTLV III/LAV)]. The resulting spectrum of immune deficiency sets the stage for opportunistic infection and malignancy. In this review, we consider progress made in the treatment and prevention of AIDS and HTLV III/LAV infection. Immunomodulator and antiviral approaches are discussed.

Citing Articles

Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.

Lapushin R, Totpal K, Higuchi M, Aggarwal B J Clin Immunol. 1994; 14(1):39-49.

PMID: 8132736 DOI: 10.1007/BF01541174.

Human immunodeficiency virus (HIV) infection for the general physician.

Gilson R, Weller I Postgrad Med J. 1987; 63(740):427-33.

PMID: 3501581 PMC: 2428303. DOI: 10.1136/pgmj.63.740.427.

References

Francis D, Petricciani J . The prospects for and pathways toward a vaccine for AIDS. N Engl J Med. 1985; 313(25):1586-90. DOI: 10.1056/NEJM198512193132506. View

Gupta S, Gillis S, Thornton M, Goldberg M . Autologous mixed lymphocyte reaction in man. XIV. Deficiency of the autologous mixed lymphocyte reaction in acquired immune deficiency syndrome (AIDS) and AIDS related complex (ARC). In vitro effect of purified interleukin-1 and interleukin-2. Clin Exp Immunol. 1984; 58(2):395-401. PMC: 1577069. View

Gupta S . Study of activated T cells in man. II. Interleukin 2 receptor and transferrin receptor expression on T cells and production of interleukin 2 in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Clin Immunol Immunopathol. 1986; 38(1):93-100. DOI: 10.1016/0090-1229(86)90126-1. View

Davis K, Hayward A, Ozturk G, Kohler P . Lymphocyte transfusion in case of acquired immunodeficiency syndrome. Lancet. 1983; 1(8324):599-600. DOI: 10.1016/s0140-6736(83)92855-6. View

Ratner L, Haseltine W, Patarca R, Livak K, Starcich B, Josephs S . Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 1985; 313(6000):277-84. DOI: 10.1038/313277a0. View

Moore N, Patzer E, Shaw J, Thompson T, Wagner R . Interaction of vesicular stomatitis virus with lipid vesicles: depletion of cholesterol and effect on virion membrane fluidity and infectivity. J Virol. 1978; 27(2):320-9. PMC: 354170. DOI: 10.1128/JVI.27.2.320-329.1978. View

Alter H, Eichberg J, Masur H, Saxinger W, Gallo R, Macher A . Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science. 1984; 226(4674):549-52. DOI: 10.1126/science.6093251. View

Rook A, Hooks J, Quinnan G, Lane H, Manischewitz J, Macher A . Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. J Immunol. 1985; 134(3):1503-7. View

Gelmann E, Preble O, Steis R, Lane H, Rook A, Wesley M . Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. Am J Med. 1985; 78(5):737-41. DOI: 10.1016/0002-9343(85)90276-1. View

10.

Hicks D, Martin L, Getchell J, Heath J, Francis D, McDougal J . Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet. 1985; 2(8469-70):1422-3. DOI: 10.1016/s0140-6736(85)92584-x. View

11.

Bowen D, Lane H, Fauci A . Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103(5):704-9. DOI: 10.7326/0003-4819-103-5-704. View

12.

Gallo R, Salahuddin S, Popovic M, Shearer G, Kaplan M, Haynes B . Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984; 224(4648):500-3. DOI: 10.1126/science.6200936. View

13.

Dalgleish A, Beverley P, Clapham P, Crawford D, Greaves M, Weiss R . The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312(5996):763-7. DOI: 10.1038/312763a0. View

14.

Pompidou A, Zagury D, Gallo R, Sun D, Thornton A, SARIN P . In-vitro inhibition of LAV/HTLV-III infected lymphocytes by dithiocarb and inosine pranobex. Lancet. 1985; 2(8469-70):1423. DOI: 10.1016/s0140-6736(85)92585-1. View

15.

Rook A, Masur H, Lane H, Frederick W, Kasahara T, Macher A . Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983; 72(1):398-403. PMC: 1129196. DOI: 10.1172/jci110981. View

16.

Hassett J, Zaroulis C, Greenberg M, Siegal F . Bone-marrow transplantation in AIDS. N Engl J Med. 1983; 309(11):665. DOI: 10.1056/NEJM198309153091114. View

17.

Klatzmann D, Barre-Sinoussi F, Nugeyre M, Danquet C, Vilmer E, Griscelli C . Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984; 225(4657):59-63. DOI: 10.1126/science.6328660. View

18.

Broder S, Yarchoan R, Collins J, Lane H, Markham P, Klecker R . Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet. 1985; 2(8456):627-30. DOI: 10.1016/s0140-6736(85)90002-9. View

19.

Beldekas J, Levy E, Black P, von Krogh G, Sandstrom E . In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS. Lancet. 1985; 2(8464):1128-9. DOI: 10.1016/s0140-6736(85)90719-6. View

20.

Muesing M, Smith D, Cabradilla C, Benton C, Lasky L, Capon D . Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature. 1985; 313(6002):450-8. DOI: 10.1038/313450a0. View